Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy

NCT05005650CompletedOBSERVATIONAL

Summary

Key Facts

Lead Sponsor

Seoul National University Hospital

Enrollment

121

Start Date

2021-06-01

Completion Date

2021-08-31

Study Type

OBSERVATIONAL

Official Title

Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy on Stage IVB Ovarian Cancer With Supradiaphragmatic Lymph Node Metastasis

Interventions

debulking surgery

Conditions

Ovarian Cancer Stage IVLymph Node Metastases

Eligibility

Age Range

18 Years – 90 Years

Sex

FEMALE

Inclusion Criteria:

* Histologically diagnosed ovarian, fallopian tubal, primary peritoneal cancer
* Patients suspected of metastatic lymph nodes in the cardiophrenic, internal mammary, and/or supraclavicular lymph node by CT (size larger than 5mm)
* Patients clinically diagnosed FIGO stage IVB ovarian, fallopian tubal, primary peritoneal cancer
* Patients underwent debulking surgery (primary debulking surgery or interval debulking surgery) at Seoul National University Hospital from January 2010 to January 2020
* Patients age 18-90

Exclusion Criteria:

* Borderline or benign ovarian disease
* Patient didn't undergo debulking surgery
* Non-epithelial ovarian cancer

Outcome Measures

Primary Outcomes

Progression-free survival

the time interval from the treatment start date to disease recurrence or progression date

Time frame: From date of treatment until the date of first documented progression or date of death (by any cause, in the absence of disease progression) whichever came first, assessed up to 120 months

Secondary Outcomes

Overall survival

the time interval from the treatment start date to death or end of study date

Time frame: From the date of treatment start date until death due to any cause, assessed up to 120 months

Locations

Seoul National University Hospital, Seoul, South Korea

Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy